Clinical trials: Poor Performance Status
Deep Vein Thrombosis, Cancer
US-Doppler and Procoagulant Microparticles for the Diagnosis of Asymptomatic DVT in Advanced Cancer Patients With Poor Performance Status
The aim of this study is to determine the prevalence of asymptomatic lower extremity DVT detected by US-Doppler and procoagulant microparticles in a selected group of cancer patients suffering from an advanced stage of the…
- Trial name
- NCT00336258
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status
The goal of this clinical trial is to learn if the drug Toripalimab can prime the tumor to optimize response to Paclitaxel in HNSCC patients with a decrease performance status in a way that make both drugs well tolerated and…
- Trial name
- HNSCC (NCT07796126)
- Testing
- Toripalimab, Paclitaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Cancer
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00006259
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in Korea. Although there is standard therapy, which is called 'R-CHOP', many obstacles to use aggressive cytotoxic chemotherapeutic agents such…
- Trial name
- NCT01676558
- Testing
- 131I-rituximab
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- Korea Cancer Center Hospital
NSCLC
Iressa v BSC (Best Supportive Care) in First Line NSCLC
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.
- Trial name
- INSTEP (NCT00259064)
- Testing
- Gefitinib
- Where
- 36 sites in Australia, Canada and 3 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Lung Cancer
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
The goal of this clinical research study is to learn how effective the drug pemetrexed (ALIMTA®) is in treating advanced NSCLC in patients with poor performance status (PS) (inability to perform every day activities without…
- Trial name
- NCT00508144
- Testing
- Alimta
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme
Radiosurgery for Glioblastoma Multiforme
Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor…
- Trial name
- NCT00456612
- Testing
- CyberKnife
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Deaconess Medical Center